Patents by Inventor Nicholas J. S. Huby

Nicholas J. S. Huby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sultam derivatives
    Patent number: 8314250
    Abstract: The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: November 20, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kevin W. Anderson, Paul Gillespie, Nicholas J. S. Huby, Norman Kong, John L. Roberts, Pamela L. Rossman, Sung-Sau So
  • Substituted hydantoins
    Patent number: 8063085
    Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: November 22, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, John Anthony Moliterni, Omar Jose Morales
  • SULTAM DERIVATIVES
    Publication number: 20110124686
    Abstract: The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.
    Type: Application
    Filed: October 15, 2010
    Publication date: May 26, 2011
    Inventors: Kevin W. Anderson, Paul Gillespie, Nicholas J. S. Huby, Norman Kong, John L. Roberts, Pamela L. Rossman, Sung-Sau So
  • Substituted hydantoins
    Patent number: 7612212
    Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: November 3, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, Steven Gregory Mischke, John Anthony Moliterni, Hong Wang, Zhuming Zhang
  • Substituted hydantoins
    Patent number: 7557221
    Abstract: This invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK2, protein kinases that are components of the MAP kinase signal transduction pathway and as such the compounds will have anti-hyperproliferative cellular activity.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 7, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, John Anthony Moliterni, Omar Jose Morales
  • SUBSTITUTED HYDANTOINS
    Publication number: 20090170920
    Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
    Type: Application
    Filed: December 10, 2008
    Publication date: July 2, 2009
    Inventors: Shaoqing Chen, Nicholas J.S. Huby, Norman Kong, Jonh Anthony Moliterni, Omar Jose Morales
  • SUBSTITUTED HYDANTOINS
    Publication number: 20090048452
    Abstract: This invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK2, protein kinases that are components of the MAP kinase signal transduction pathway and as such the compounds will have anti-hyperproliferative cellular activity.
    Type: Application
    Filed: August 6, 2008
    Publication date: February 19, 2009
    Inventors: Shaoqing Chen, Nicholas J.S. Huby, Norman Kong, John Anthony Moliterni, Omar Jose Morales
  • Substituted hydantoins
    Patent number: 7427635
    Abstract: The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: September 23, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Xin-Jie Chu, Nader Fotouhi, Nicholas J. S. Huby, Norman Kong, Lee Apostle McDermott, John Moliterni, Zhuming Zhang
  • Substituted hydantoins
    Patent number: 7371869
    Abstract: The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: May 13, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Robert Alan Goodnow, Jr., Nicholas J. S. Huby, Norman Kong, Lee Apostle McDermott, John Anthony Moliterni, Zhuming Zhang
  • Substituted hydantoins
    Publication number: 20070197617
    Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
    Type: Application
    Filed: January 25, 2007
    Publication date: August 23, 2007
    Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, Steven Gregory Mischke, John Anthony Moliterni, Hong Wang, Zhuming Zhang
  • Sulfonamide substituted xanthine derivatives
    Patent number: 7148229
    Abstract: The present invention is a sulfonamide substituted xanthine derivative of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is lower alkyl, lower alkyl substituted by phenyl, or lower alkyl substituted by halogen substituted phenyl; R2 is lower alkyl or lower alkyl substituted by lower cycloalkyl; and R3 is: Compounds of formula I and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: December 12, 2006
    Assignee: Hoffman-La Roche Inc.
    Inventors: Peter W. Dunten, Louise H. Foley, Nicholas J. S. Huby, Sherrie L. Pietranico-Cole, Weiya Yun
  • Amide substituted xanthine derivatives
    Patent number: 7135475
    Abstract: The present invention is a 1,3,8 substituted xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula I and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: November 14, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter W. Dunten, Louise H. Foley, Nicholas J. S. Huby, Sherrie L. Pietranico-Cole, Weiya Yun
  • Sulfonamide substituted xanthine derivatives
    Publication number: 20040192708
    Abstract: The present invention is a sulfonamide substituted xanthine derivative of formula I 1
    Type: Application
    Filed: February 11, 2004
    Publication date: September 30, 2004
    Inventors: Peter W. Dunten, Louise H. Foley, Nicholas J. S. Huby, Sherrie L. Pietranico-Cole, Weiya Yun
  • Amide substituted xanthine derivatives
    Publication number: 20040014766
    Abstract: The present invention is a 1,3,8 substituted xanthine derivative of formula I 1
    Type: Application
    Filed: June 12, 2003
    Publication date: January 22, 2004
    Inventors: Peter W. Dunten, Louise H. Foley, Nicholas J.S. Huby, Sherrie L. Pietranico-Cole, Weiya Yun